Table 4.
Adverse events between the two treatment groups.
| Variable | RFA-Sorafenib (n = 103) | RFA (n = 108) | P-value |
|---|---|---|---|
| Grade 1–2/3–4 (%/%) | |||
| Pain | 52/2 (50.5/1.9) | 59/4 (54.6/3.7) | 0.518 |
| Pleural effusion | 1/2 (1.0/1.9) | 1/1 (0.9/0.9) | 1.000 |
| Gastrointestinal bleeding | 1/2 (1.0/1.9) | 1/1 (0.9/0.9) | 1.000 |
| Fever | 19/2 (18.4/1.9) | 22/0 (20.4/0) | 0.233 |
| Hand-foot skin reactions | 27/10 (26.2/9.7) | 0/0 (0/0) | – |
| Diarrhea | 43/9 (41.7/8.7) | 0/0 (0/0) | – |
| Hypertension | 21/4 (20.4/3.9) | 0/0 (0/0) | – |
| Alopecia | 18/4 (17.5/3.9) | 0/0 (0/0) | – |
| Nausea/vomiting | 48/2 (46.6/1.9) | 0/0 (0/0) | – |
| Fatigue | 29/8 (28.2/7.8) | 0/0 (0/0) | – |
| Dysphonia | 6/1 (5.8/1.0) | 0/0 (0/0) | – |
| Decreased appetite | 45/9 (43.7/8.7) | 0/0 (0/0) | – |
| Pyrexia | 18/1 (17.5/1.0) | 0/0 (0/0) | – |
| Rash | 22/1 (21.4/1.0) | 0/0 (0/0) | – |
| Weight decreased | 19/1 (18.4/1.0) | 0/0 (0/0) | – |
| Headache | 8/1 (7.8/1.0) | 0/0 (0/0) | – |
| ALT increased | 40/11 (38.8/10.7) | 0/0 (0/0) | – |
| Hyperbilirubinemia | 19/2 (18.4/1.9) | 0/0 (0/0) | – |
| Constipation | 13/1 (12.6/1.0) | 0/0 (0/0) | – |
| Oral mucositis | 15/1 (14.6/1.0) | 0/0 (0/0) | – |
RFA, radiofrequency ablation; ALT, alanine aminotransferase.